세계의 mRNA 의약 시장 조사 보고서 : 산업 분석, 규모, 점유율, 성장, 동향, 예측(2024-2032년)

The global demand for mRNA Therapeutics Market is presumed to reach the market size of nearly USD 49.82 Billion by 2032 from USD 12.23 Billion in 2023 with a CAGR of 16.89% under the study period 2024-2032.

mRNA therapeutics is a class of drugs that utilize messenger RNA (mRNA) molecules to instruct cells to produce therapeutic proteins or antigens within the body. These mRNA-based drugs offer a novel approach to treating diseases by harnessing the body's natural protein synthesis machinery to produce specific therapeutic molecules. These drugs hold promise for a wide range of applications, including vaccines, cancer immunotherapy, protein replacement therapy, and regenerative medicine.

MARKET DYNAMICS

The growing interest and investment in mRNA-based drug development drives the market for mRNA therapeutics. The versatility and potential of mRNA technology to address unmet medical needs, including infectious diseases, cancer, genetic disorders, and rare diseases, fuel market growth. mRNA therapeutics offer a novel approach to drug development by harnessing the body's natural protein synthesis machinery to produce therapeutic proteins or antigens within cells, enabling targeted and customizable treatment strategies. Moreover, advancements in mRNA delivery systems, lipid nanoparticle formulations, and mRNA stabilization techniques enhance therapeutic efficacy, bioavailability, and safety profiles, driving market adoption.

Additionally, the rapid development and regulatory approval of mRNA-based COVID-19 vaccines demonstrate the feasibility and scalability of mRNA technology for vaccine development, accelerating investment and research in mRNA therapeutics for other diseases. Furthermore, collaborations between pharmaceutical companies, biotechnology firms, academic research institutions, and government agencies propel innovation & pipeline development in mRNA drug discovery, further stimulating market growth. However, regulatory hurdles, manufacturing complexities, and public perception concerns regarding genetic therapies may challenge the market growth in the coming years.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of mRNA Therapeutics. The growth and trends of mRNA Therapeutics industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the mRNA Therapeutics market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Application

• Infectious Diseases
• Oncology
• Rare Genetic Diseases
• Respiratory Diseases
• Others

By Type

• Prophylactic
• Therapeutic

By End-use

• Hospitals & Clinics
• Research Organizations
• Others

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the mRNA Therapeutics market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the mRNA Therapeutics market include Moderna Inc., BioNTech SE, CureVac N.V., Arcturus Therapeutics, Sanofi, GSK Plc., Argos Therapeutics Inc., Ethris, Pfizer Inc., AstraZeneca. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1. PREFACE

• 1.1. Report Description
  • 1.1.1 Objective
  • 1.1.2 Target Audience
  • 1.1.3 Unique Selling Proposition (USP) & offerings
• 1.2. Research Scope
• 1.3. Research Methodology
  • 1.3.1 Market Research Process
  • 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

• 2.1. Highlights of Market
• 2.2. Global Market Snapshot

3. MRNA THERAPEUTICS - INDUSTRY ANALYSIS

• 3.1. Introduction - Market Dynamics
• 3.2. Market Drivers
• 3.3. Market Restraints
• 3.4. Opportunities
• 3.5. Industry Trends
• 3.6. Porter's Five Force Analysis
• 3.7. Market Attractiveness Analysis
  • 3.7.1 Market Attractiveness Analysis By Application
  • 3.7.2 Market Attractiveness Analysis By Type
  • 3.7.3 Market Attractiveness Analysis By End-use
  • 3.7.4 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

• 4.1. Value Chain Analysis
• 4.2. Raw Material Analysis
  • 4.2.1 List of Raw Materials
  • 4.2.2 Raw Material Manufactures List
  • 4.2.3 Price Trend of Key Raw Materials
• 4.3. List of Potential Buyers
• 4.4. Marketing Channel
  • 4.4.1 Direct Marketing
  • 4.4.2 Indirect Marketing
  • 4.4.3 Marketing Channel Development Trend

5. GLOBAL MRNA THERAPEUTICS MARKET ANALYSIS BY APPLICATION

• 5.1. Overview By Application
• 5.2. Historical and Forecast Data
• 5.3. Analysis By Application
• 5.4. Infectious Diseases Historic and Forecast Sales By Regions
• 5.5. Oncology Historic and Forecast Sales By Regions
• 5.6. Rare Genetic Diseases Historic and Forecast Sales By Regions
• 5.7. Respiratory Diseases Historic and Forecast Sales By Regions
• 5.8. Others Historic and Forecast Sales By Regions

6. GLOBAL MRNA THERAPEUTICS MARKET ANALYSIS BY TYPE

• 6.1. Overview By Type
• 6.2. Historical and Forecast Data
• 6.3. Analysis By Type
• 6.4. Prophylactic Historic and Forecast Sales By Regions
• 6.5. Therapeutic Historic and Forecast Sales By Regions

7. GLOBAL MRNA THERAPEUTICS MARKET ANALYSIS BY END-USE

• 7.1. Overview By End-use
• 7.2. Historical and Forecast Data
• 7.3. Analysis By End-use
• 7.4. Hospitals & Clinics Historic and Forecast Sales By Regions
• 7.5. Research Organizations Historic and Forecast Sales By Regions
• 7.6. Others Historic and Forecast Sales By Regions

8. GLOBAL MRNA THERAPEUTICS MARKET ANALYSIS BY GEOGRAPHY

• 8.1. Regional Outlook
• 8.2. Introduction
• 8.3. North America Sales Analysis
  • 8.3.1 Overview, Historic and Forecast Data Sales Analysis
  • 8.3.2 North America By Segment Sales Analysis
  • 8.3.3 North America By Country Sales Analysis
  • 8.3.4 United States Sales Analysis
  • 8.3.5 Canada Sales Analysis
  • 8.3.6 Mexico Sales Analysis
• 8.4. Europe Sales Analysis
  • 8.4.1 Overview, Historic and Forecast Data Sales Analysis
  • 8.4.2 Europe By Segment Sales Analysis
  • 8.4.3 Europe By Country Sales Analysis
  • 8.4.4 United Kingdom Sales Analysis
  • 8.4.5 France Sales Analysis
  • 8.4.6 Germany Sales Analysis
  • 8.4.7 Italy Sales Analysis
  • 8.4.8 Russia Sales Analysis
  • 8.4.9 Rest Of Europe Sales Analysis
• 8.5. Asia Pacific Sales Analysis
  • 8.5.1 Overview, Historic and Forecast Data Sales Analysis
  • 8.5.2 Asia Pacific By Segment Sales Analysis
  • 8.5.3 Asia Pacific By Country Sales Analysis
  • 8.5.4 China Sales Analysis
  • 8.5.5 India Sales Analysis
  • 8.5.6 Japan Sales Analysis
  • 8.5.7 South Korea Sales Analysis
  • 8.5.8 Australia Sales Analysis
  • 8.5.9 South East Asia Sales Analysis
  • 8.5.10 Rest Of Asia Pacific Sales Analysis
• 8.6. Latin America Sales Analysis
  • 8.6.1 Overview, Historic and Forecast Data Sales Analysis
  • 8.6.2 Latin America By Segment Sales Analysis
  • 8.6.3 Latin America By Country Sales Analysis
  • 8.6.4 Brazil Sales Analysis
  • 8.6.5 Argentina Sales Analysis
  • 8.6.6 Peru Sales Analysis
  • 8.6.7 Chile Sales Analysis
  • 8.6.8 Rest of Latin America Sales Analysis
• 8.7. Middle East & Africa Sales Analysis
  • 8.7.1 Overview, Historic and Forecast Data Sales Analysis
  • 8.7.2 Middle East & Africa By Segment Sales Analysis
  • 8.7.3 Middle East & Africa By Country Sales Analysis
  • 8.7.4 Saudi Arabia Sales Analysis
  • 8.7.5 UAE Sales Analysis
  • 8.7.6 Israel Sales Analysis
  • 8.7.7 South Africa Sales Analysis
  • 8.7.8 Rest Of Middle East And Africa Sales Analysis

9. COMPETITIVE LANDSCAPE OF THE MRNA THERAPEUTICS COMPANIES

• 9.1. MRNA Therapeutics Market Competition
• 9.2. Partnership/Collaboration/Agreement
• 9.3. Merger And Acquisitions
• 9.4. New Product Launch
• 9.5. Other Developments

10. COMPANY PROFILES OF MRNA THERAPEUTICS INDUSTRY

• 10.1. Top Companies Market Share Analysis
• 10.2. Market Concentration Rate
• 10.3. Moderna Inc.
  • 10.3.1 Company Overview
  • 10.3.2 Company Revenue
  • 10.3.3 Products
  • 10.3.4 Recent Developments
• 10.4. BioNTech SE
  • 10.4.1 Company Overview
  • 10.4.2 Company Revenue
  • 10.4.3 Products
  • 10.4.4 Recent Developments
• 10.5. CureVac N.V.
  • 10.5.1 Company Overview
  • 10.5.2 Company Revenue
  • 10.5.3 Products
  • 10.5.4 Recent Developments
• 10.6. Arcturus Therapeutics
  • 10.6.1 Company Overview
  • 10.6.2 Company Revenue
  • 10.6.3 Products
  • 10.6.4 Recent Developments
• 10.7. Sanofi
  • 10.7.1 Company Overview
  • 10.7.2 Company Revenue
  • 10.7.3 Products
  • 10.7.4 Recent Developments
• 10.8. GSK Plc.
  • 10.8.1 Company Overview
  • 10.8.2 Company Revenue
  • 10.8.3 Products
  • 10.8.4 Recent Developments
• 10.9. Argos Therapeutics Inc.
  • 10.9.1 Company Overview
  • 10.9.2 Company Revenue
  • 10.9.3 Products
  • 10.9.4 Recent Developments
• 10.10. Ethris
  • 10.10.1 Company Overview
  • 10.10.2 Company Revenue
  • 10.10.3 Products
  • 10.10.4 Recent Developments
• 10.11. Pfizer Inc.
  • 10.11.1 Company Overview
  • 10.11.2 Company Revenue
  • 10.11.3 Products
  • 10.11.4 Recent Developments
• 10.12. AstraZeneca
  • 10.12.1 Company Overview
  • 10.12.2 Company Revenue
  • 10.12.3 Products
  • 10.12.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies